Luxturna maintained long-term improvements in ambulatory vision, light sensitivity and visual field in patients with biallelic RPE65 mutation-associated retinal diseases, according to a study.
The phase 3 study was designed to investigate the long-term efficacy and safety of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) in two cohorts: an original intervention group that underwent a 9-year follow-up (20 patients) and a delayed intervention group that underwent an 8-year follow-up (nine patients), Stephen R. Russell, MD, of the University of Iowa, said at the American Society of